Repare Therapeutics Inc
NASDAQ:RPTX
Intrinsic Value
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient population... [ Read More ]
The intrinsic value of one RPTX stock under the Base Case scenario is 6.65 USD. Compared to the current market price of 3.15 USD, Repare Therapeutics Inc is Undervalued by 53%.
Valuation Backtest
Repare Therapeutics Inc
Run backtest to discover the historical profit from buying and selling RPTX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Repare Therapeutics Inc
Current Assets | 243.7m |
Cash & Short-Term Investments | 223.6m |
Receivables | 15.3m |
Other Current Assets | 4.7m |
Non-Current Assets | 10.2m |
PP&E | 7.5m |
Other Non-Current Assets | 2.7m |
Current Liabilities | 39.1m |
Accounts Payable | 2.4m |
Accrued Liabilities | 26.3m |
Other Current Liabilities | 10.4m |
Non-Current Liabilities | 2.7m |
Other Non-Current Liabilities | 2.7m |
Earnings Waterfall
Repare Therapeutics Inc
Revenue
|
51.1m
USD
|
Operating Expenses
|
-167.4m
USD
|
Operating Income
|
-116.2m
USD
|
Other Expenses
|
22.4m
USD
|
Net Income
|
-93.8m
USD
|
Free Cash Flow Analysis
Repare Therapeutics Inc
What is Free Cash Flow?
RPTX Profitability Score
Profitability Due Diligence
Repare Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Repare Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
RPTX Solvency Score
Solvency Due Diligence
Repare Therapeutics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Repare Therapeutics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RPTX Price Targets Summary
Repare Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for RPTX is 18.02 USD with a low forecast of 8.08 USD and a high forecast of 30.45 USD.
Ownership
RPTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
RPTX Price
Repare Therapeutics Inc
Average Annual Return | -20.04% |
Standard Deviation of Annual Returns | 32.68% |
Max Drawdown | -93% |
Market Capitalization | 132.9m USD |
Shares Outstanding | 42 182 200 |
Percentage of Shares Shorted | 2.72% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 152 full-time employees. The company went IPO on 2020-06-19. The firm is focused on the development of synthetic lethality (SL) based therapies to patients with cancer. The company uses genome wide, SNIPRx platform to systematically discover and develop targeted cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The firm is developing its pipeline of SL product candidates, including its lead product candidate, RP-3500, a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related (ATR) protein kinase for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated (ATM) kinase gene. Its preclinical programs include RP-6306 Protein Kinase Membrane-associated tYrosine- and Threonine- specific cdc-2 inhibitory (PKMYT1)kinase SL inhibitor, in advanced solid tumors.
Contact
IPO
Employees
Officers
The intrinsic value of one RPTX stock under the Base Case scenario is 6.65 USD.
Compared to the current market price of 3.15 USD, Repare Therapeutics Inc is Undervalued by 53%.